Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RNAZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $66.33
Previous CloseN/A
Volume52.57K
Average Volume (3M)9.04M
Market Cap
$779.80K
Enterprise Value$6.66M
Total Cash (Recent Filing)$204.47K
Total Debt (Recent Filing)$927.81K
Price to Earnings (P/E)―
Beta3.38
Next Earnings
Mar 28, 2025EPS Estimate
-105.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-265.83
Shares Outstanding696,249
10 Day Avg. Volume25,921,868
30 Day Avg. Volume9,038,536
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap8.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.89
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$20.00Price Target Upside1685.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Financial PerformanceAn NIH grant of $2M was awarded to the company to assist in funding the trial.
Strategic PartnershipsThe company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.
Bears Say
Investor SentimentInvestors may be disappointed with not seeing initial responses.
Market RisksThere is a de-listing risk if shares go under $1.
---
Ownership Overview
8.49%
Insiders
5.43%
Mutual Funds
― Other Institutional Investors
91.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $0.65 and its highest was $66.33 in the past 12 months.
What is TransCode Therapeutics’s market cap?
TransCode Therapeutics’s market cap is $779.80K.
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is in 3 days.
How were TransCode Therapeutics’s earnings last quarter?
TransCode Therapeutics released its earnings results on Nov 11, 2024. The company reported -$5.28 earnings per share for the quarter, beating the consensus estimate of -$16.17 by $10.89.
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -105.93.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 696,249 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
TransCode Therapeutics reported an EPS of -$5.28 in its last earnings report, beating expectations of -$16.17. Following the earnings report the stock price went down -12.067%.
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
---
Company Description
TransCode Therapeutics
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
---
RNAZ Stock 12 Month Forecast
Average Price Target
$20.00
▲(1685.71% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering RNAZ
1 Year
1 Year Success Rate
0/17 ratings generated profit
1 Year Average Return
-89.42%
reiterated a buy rating 13 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -89.42% per trade.
---